A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Sarisol, Butisol, Butisol sodium, Busodium, Butalan, Buticaps
Synonyms :
Secobutabarbitone sodium
Class :
Sedative/hypnotics, Barbiturates
Brand Name :
Sarisol, Butisol, Butisol sodium, Busodium, Butalan, Buticaps
Synonyms :
Secobutabarbitone sodium
Class :
Sedative/hypnotics, Barbiturates
Dosage Forms & StrengthsÂ
Tablets (Schedule-III)Â
15mgÂ
30mgÂ
50mgÂ
100mgÂ
Elixirs (Schedule-III)Â
30mg/5mlÂ
Day time: 15mg to 30mg orally every 6hours – 8hours daily for 2weeks
Sedation before surgery: 50mg to 100mg orally one time an hour to one and half-an-hour before operation
Note: a typical loss in maintenance and sleep induction can be lost after 2 weeks therapy when it is used as a daytime sedative
Short time of this drug is recommended
50mg to 100mg orally one time in a day at bedtime for 14days
Note: a typical loss in maintenance and sleep induction can be lost after 2 weeks therapy when it is used in treating insomnia
To be used only for short-term
Dosage Forms & StrengthsÂ
Tablets (Schedule-III)Â
15mgÂ
30mgÂ
50mgÂ
100mgÂ
Elixirs (Schedule-III)Â
30mg/5mlÂ
2-6mg/kg, orally one hour to one and half-an- hour before surgery
Note: Maximum dose not exceeding 100mg
Lower dose range can be suggested. To be used with caution in geriatric populationÂ
A lower dose range can be suggested. To be used with caution in geriatric population
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
may increase the metabolism of vitamin K antagonists
It may diminish the effect when combined with lonafarnib by affecting CYP3A4 metabolism
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
may enhance the metabolism when combined with tricyclic antidepressants
calcium, magnesium, potassium and sodium oxybateÂ
by the way of pharmacodynamic synergism, the effects of sedation can be raised when butabarbital is combined with sodium/potassiu/magnesium/calcium oxybates
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of fostemsavir can be reduced by butabarbital
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of isavuconazonium sulfate can be reduced by butabarbital
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of mavacamten can be reduced by butabarbital
may increase the CNS depressant effect
may increase the CNS depressant effect
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
may increase the metabolism of tricyclic antidepressants
It may diminish the effect when combined with pemigatinib by affecting CYP3A4 metabolism
butabarbital can diminish the level or impact of intranasal dihydroergotamine by influencing the metabolism of the hepatic/intestinal enzyme CYP3A4
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of abemaciclib can be reduced by butabarbital
the activity of antithrombin alfa is reduced by butabarbital by enhancing metabolism
the activity of bivaluridin is reduced by butabarbital by enhancing metabolism
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of copanlisib can be reduced by butabarbital
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of dihydroergotamine can be reduced by butabarbital
by altering intestinal/hepatic CYP 1A2 metabolism, the activity of duloxetine can be reduced by butabarbital
the activity of enoxaparin is reduced by butabarbital by enhancing metabolism
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of ethinylestradiol can be reduced by butabarbital
by pharmacodynamic synergism, the activity of either of the drugs will be increased
the activity of heparin is reduced by butabarbital by enhancing metabolism
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of lenacapavir can be reduced by butabarbital
the activity of mestranol is reduced by butabarbital by enhancing metabolism
when both drugs are combined, there may be an increasing effect of alpelisib by affecting hepatic or intestinal enzyme cyp3a4 metabolism   
when both drugs are combined, there may be a reduced level or effect of romidepsin by affecting hepatic or intestinal enzyme cyp3a4 metabolism  
it increases the effect of CNS depressants
it increases the effect of CNS depressants
CNS depressants increase the CNS depressing effect of thalidomide
may reduce the therapeutic effect of hemin
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
Barbiturates may enhance the hypotensive effect of Blood Pressure Lowering Agents
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the metabolism of Vitamin K Antagonists
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
may increase the hypotensive effect
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
barbiturates may increase the metabolism of tricyclic antidepressants
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
It may enhance sedation when combined with perphenazine
it may diminish the excretion rate when combined with permethrin, resulting in an enhanced serum level
It may enhance the effect when combined with cannabidiol by affecting CYP3A4 metabolism
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
may have an increased hypotensive effect when combined with antihypertensive agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
barbiturates: they may increase the hypotensive effect when combined with blood viscoosity-reducing agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
they increase the effect of hypotension of BP-lowering agents
The potential for increased CNS depression risk or seriousness occurs when butabarbital is used together with pinazepam
The potential for increased CNS depression risk or seriousness occurs when butabarbital is used together with pipecuronium
When butabarbital is used together with bromisoval, the risk or seriousness of CNS depression is enhanced
butabarbital has the potential to reduce the rate of excretion of idebenone, leading to an elevation in levels of serum
When captodiame is used together with butabarbital, there is a risk or seriousness of CNS depression is enhanced
When butabarbital is used together with medazepam, the risk or seriousness of CNS depression is enhanced
The potential for CNS depression may enhanced when butabarbital is used together with fencamfamin
When butabarbital is used together with niaprazine, the risk or seriousness of CNS depression is enhanced
When butabarbital is used together with levosulpiride, the risk or seriousness of CNS depression is enhanced
When chlordiazepoxide is used together with butabarbital, this leads to enhanced risk or seriousness of CNS depression
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
barbiturates: they may decrease the therapeutic effect of antipsychotics
butabarbitol: they may increase the toxic effect of mu-opioid receptor agonists
butabarbitol: they may increase the toxic effect of mu-opioid receptor agonists
When emylcamate is used together with butabarbital, this leads to enhanced risk or seriousness of CNS depression
When butabarbital is used together with etizolam, this leads to enhanced risk or seriousness of CNS depression
When acepromazine is used together with butabarbital, this leads to enhanced risk or seriousness of CNS depression
cefpirome leads to a reduction in the rate of excretion of butabarbital which leads to increased level of serum
butabarbital leads to a reduction in the rate of excretion of chromous sulfate, which leads to an increased level of serum
butabarbital leads to a reduction in the rate of excretion of pentaerythritol tetranitrate, which leads to an increased level of serum
butabarbital leads to a reduction in the rate of excretion of potassium acetate, which leads to an increased level of serum
butabarbital leads to a reduction in the rate of excretion of potassium perchlorate, which leads to an increased level of serum
butabarbital: it may increase the risk or severity of CNS depression
butabarbital: it may increase the risk or severity of CNS depression
butabarbital: it may increase the risk or severity of CNS depression
butabarbital: it may increase the risk or severity of CNS depression
butabarbital: it may increase the risk or severity of CNS depression
When butabarbital is used together with profenamine, this leads to enhanced risk or seriousness of adverse events
hepatic enzyme metabolism i.e., CYP3A4 metabolism is affected when butabarbital used combinely with lidocaine and lowering its levels
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of doravirine can be reduced by butabarbital
by altering intestinal/hepatic CYP 3A4 metabolism, the activity of avapritinib can be reduced by butabarbital
butabarbital may decrease the excretion rate of almasilate, leading to higher serum levels
when both drugs combine butabarbital will increase effect of ifosfamide by affecting the enzyme CYP3A4 metabolism.
cyclophosphamide effect of action decreased by affecting enzyme CYP3A4 metabolism
butabarbital may increase the hypotensive activities of paclitaxel 
they increase the effect of hypotension on other hypotensive agents
they increase the effect of hypotension on other hypotensive agents
they increase the metabolism of norepinephrine reuptake inhibitors
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
may enhance the hypotensive effect of blood Pressure Lowering Agents
valproate increases the concentration of serum barbiturates in the serum
glycopyrrolate inhaled and formoterolÂ
may decrease the toxic effects of each other by sedation
may increase the sedative effect of CNS depressants
may increase the hypotensive effect of antihypertensives
may increase the hypotensive effect of anti-hypertensives
may increase the hypotensive effect of blood pressure-lowering agents
hydrochlorothiazide/aliskirenÂ
may increase the hypotensive effect of blood pressure-lowering agents
lisinopril/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
eprosartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
valsartan/hydrochlorothiazideÂ
may increase the hypotensive effect of blood pressure-lowering agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may have an increased hypotensive effect when combined with anti-hypertensive agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
may increase the hypotensive effect of Blood Pressure Lowering Agents
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
It may enhance the risk of adverse effects when combined with Barbiturates
may increase the hypotensive effect of barbiturates
serum levels of bufylline can be reduced with butabarbital
butabarbital might lead to a reduction in the rate of excretion of telavancin, potentially leading to elevated levels of serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
they increase the metabolism of norepinephrine reuptake inhibitors
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
CNS depressants increases the concentration of serum barbiturates in the serum
it increases the effect of CNS depressants
may decrease the level by affecting the hepatic enzyme CYP3A4 metabolism
Actions and spectrum:Â
Barbiturates, such as butabarbital, increase the neurotransmitter GABA’s (gamma-aminobutyric acid) ability to inhibit at the GABA-A receptor. This causes hyperpolarization of the neurons, which causes CNS depression.Â
Frequency not definedÂ
HeadacheÂ
HallucinationÂ
FeverÂ
SomnolocenceÂ
ApneaÂ
BradycardiaÂ
VomitingÂ
NightmaresÂ
HepatotoxicityÂ
DepressionÂ
confusionÂ
Black Box Warning Â
Do not drive or operate machines while using butabarbitalÂ
Contraindication/Caution:Â
Contraindication:Â
HypersensitivityÂ
Respiratory insufficiencyÂ
AngioedemaÂ
Hepatic impairmentÂ
Pharmacology:Â
Pharmacodynamics:Â
In order to produce sedation, butabarbital potentiates GABAergic neurons while blocking glutamate and acetylcholine receptors in individual neurons.Approximately 6 to 8 hours is the duration of action for butabarbital, an intermediate acting barbiturate. Given that patient-to-patient dose variations are significant, the therapeutic index is rather broad.Â
Pharmacokinetics:Â
AbsorptionÂ
Butabarbital undergoes rapid absorption in the gastrointestinal tractÂ
DistributionÂ
The drug is distributed mainly in the brain Â
Peak plasma concentration to produce sedation is 203µg/ml, while to induce sleep the peak plasma concentration is 25µg/mlÂ
MetabolismÂ
Butabarbital metabolized in the liverÂ
Elimination and excretionÂ
Butabarbital undergoes renal route of excretion. Most of the drug is eliminated through urineÂ
Half life:Â
Nearly 100hoursÂ
Administration:Â
Butabarbital is administered orally as a tablet or an elixir. Take the medicine at bed time after meals as advised by the physicianÂ
Patient information leafletÂ
Generic Name: butabarbital Â
Why do we use butabarbital?Â
Butabarbital is a sedative and hypnotic drug belonging to the class of barbiturates. It is used in the treatment of insomnia. During surgeries, it is employed to induce sedation 60-90minutes before surgeryÂ
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
